Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach ...

Dupixent (dupilumab) made more than €5 billion last year from its current uses in atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps, and EoE is one of a clutch ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Taurasi began using Dupixent, and it has helped her keep her eczema under control. “I was unfamiliar with the companies and with the medicine,” She said. “And as I got more familiar with ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses ...

The monoclonal antibody joins dupilumab (Dupixent) as the only approved biologics for COPD. The agency also recently approved inhaled ensifentrine (Ohtuvayre), a dual phosphodiesterase 3 and ...

Revenue received from its Dupixent collaboration partner, Sanofi, surged 30% year over year to an annualized $4.7 billion. Long-term investors could see a lot more commercial-stage products from ...

Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary ...

April 24, 2025 Sanofi's quarterly profit boosted by Dupixent and newer drugs; forecast unchanged France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday ...